Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease

Possible molecular pathways

Habib Yaribeygi, Alexandra E. Butler, Stephen Atkin, Niki Katsiki, Amirhossein Sahebkar

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Clinical trials with sodium–glucose cotransporter 2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, and canagliflozin) have shown a decrease in the progression of chronic kidney disease (CKD). SGLT2 inhibitors represent a new category of oral antidiabetic agents that can also reduce systolic and diastolic blood pressure, as well as serum uric acid, and improve the glomerular filtration rate. Apart from affecting renal hemodynamics and glycotoxicity, evidence suggests that SGLT2 inhibitors may be renoprotective due to their effects on inflammation in renal tissues. Inflammatory responses play a prominent role in the pathophysiology of CKD as several structural and functional disorders of renal failure are strongly related to the overproduction of proinflammatory mediators. The present review discusses the anti-inflammatory properties of SGLT2 inhibitors. The different molecular pathways through which SGLT2 inhibitors may affect inflammation in the kidneys are also commented upon.

Original languageEnglish
JournalJournal of Cellular Physiology
DOIs
Publication statusAccepted/In press - 1 Jan 2018

Fingerprint

Chronic Renal Insufficiency
Inflammation
Kidney
Blood pressure
Hemodynamics
Uric Acid
Hypoglycemic Agents
Blood Pressure
Anti-Inflammatory Agents
Tissue
Glomerular Filtration Rate
Renal Insufficiency
Clinical Trials
Serum
empagliflozin
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Canagliflozin

Keywords

  • canagliflozin
  • chronic kidney disease
  • dapagliflozin
  • empagliflozin
  • inflammation
  • renal failure
  • sodium–glucose cotransporter 2 inhibitors

ASJC Scopus subject areas

  • Physiology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease : Possible molecular pathways. / Yaribeygi, Habib; Butler, Alexandra E.; Atkin, Stephen; Katsiki, Niki; Sahebkar, Amirhossein.

In: Journal of Cellular Physiology, 01.01.2018.

Research output: Contribution to journalArticle

@article{3575791a86274d4da5726b86bc5f4b7d,
title = "Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways",
abstract = "Clinical trials with sodium–glucose cotransporter 2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, and canagliflozin) have shown a decrease in the progression of chronic kidney disease (CKD). SGLT2 inhibitors represent a new category of oral antidiabetic agents that can also reduce systolic and diastolic blood pressure, as well as serum uric acid, and improve the glomerular filtration rate. Apart from affecting renal hemodynamics and glycotoxicity, evidence suggests that SGLT2 inhibitors may be renoprotective due to their effects on inflammation in renal tissues. Inflammatory responses play a prominent role in the pathophysiology of CKD as several structural and functional disorders of renal failure are strongly related to the overproduction of proinflammatory mediators. The present review discusses the anti-inflammatory properties of SGLT2 inhibitors. The different molecular pathways through which SGLT2 inhibitors may affect inflammation in the kidneys are also commented upon.",
keywords = "canagliflozin, chronic kidney disease, dapagliflozin, empagliflozin, inflammation, renal failure, sodium–glucose cotransporter 2 inhibitors",
author = "Habib Yaribeygi and Butler, {Alexandra E.} and Stephen Atkin and Niki Katsiki and Amirhossein Sahebkar",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/jcp.26851",
language = "English",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease

T2 - Possible molecular pathways

AU - Yaribeygi, Habib

AU - Butler, Alexandra E.

AU - Atkin, Stephen

AU - Katsiki, Niki

AU - Sahebkar, Amirhossein

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Clinical trials with sodium–glucose cotransporter 2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, and canagliflozin) have shown a decrease in the progression of chronic kidney disease (CKD). SGLT2 inhibitors represent a new category of oral antidiabetic agents that can also reduce systolic and diastolic blood pressure, as well as serum uric acid, and improve the glomerular filtration rate. Apart from affecting renal hemodynamics and glycotoxicity, evidence suggests that SGLT2 inhibitors may be renoprotective due to their effects on inflammation in renal tissues. Inflammatory responses play a prominent role in the pathophysiology of CKD as several structural and functional disorders of renal failure are strongly related to the overproduction of proinflammatory mediators. The present review discusses the anti-inflammatory properties of SGLT2 inhibitors. The different molecular pathways through which SGLT2 inhibitors may affect inflammation in the kidneys are also commented upon.

AB - Clinical trials with sodium–glucose cotransporter 2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, and canagliflozin) have shown a decrease in the progression of chronic kidney disease (CKD). SGLT2 inhibitors represent a new category of oral antidiabetic agents that can also reduce systolic and diastolic blood pressure, as well as serum uric acid, and improve the glomerular filtration rate. Apart from affecting renal hemodynamics and glycotoxicity, evidence suggests that SGLT2 inhibitors may be renoprotective due to their effects on inflammation in renal tissues. Inflammatory responses play a prominent role in the pathophysiology of CKD as several structural and functional disorders of renal failure are strongly related to the overproduction of proinflammatory mediators. The present review discusses the anti-inflammatory properties of SGLT2 inhibitors. The different molecular pathways through which SGLT2 inhibitors may affect inflammation in the kidneys are also commented upon.

KW - canagliflozin

KW - chronic kidney disease

KW - dapagliflozin

KW - empagliflozin

KW - inflammation

KW - renal failure

KW - sodium–glucose cotransporter 2 inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85052397112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052397112&partnerID=8YFLogxK

U2 - 10.1002/jcp.26851

DO - 10.1002/jcp.26851

M3 - Article

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

ER -